Form 4: Roivant Sciences CEO Reports Stock Transaction
Insider Transaction (Form 4)
Matthew Gline, CEO and a Director of Roivant Sciences Ltd., reported a transaction in 76,171 shares of common stock on September 30, 2026.
Summary
- Tax/exercise-price withholding: disposed of 76,171 Common Shares at $36.57 ($2,785,573) on September 30, 2026; holds 16,583,774 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Matthew Gline — Director, Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Tax/exercise-price withholding | Common Shares | 76,171 | $37 | $2.8M | 16,583,774 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Tax/exercise-price withholding (76,171 shares) |
Keywords
insider transaction, Form 4, ROIV, Roivant Sciences Ltd., neutral, Matthew Gline
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.